Abstract | BACKGROUND: OBJECTIVE: To develop and evaluate a short form of the DFS (DFS-SF) to reduce patient burden and the number of outcome measures, and to improve sensitivity to change in clinical condition. METHODS: The DFS-SF was created through the analysis of data from a double-blind, placebo-controlled, randomised trial of the efficacy and safety of becaplermin (recombinant human platelet-derived growth factor BB) in the treatment of chronic, full-thickness, neuropathic, diabetic foot ulcers. Using these data, items demonstrating poor psychometric properties were eliminated. Exploratory factor analyses were then conducted to develop a new, more parsimonious scaling algorithm that optimised the internal consistency of the new subscales. Finally, data from two additional clinical trials were used to assess replicability of the DFS-SF subscale structure. RESULTS: The DFS-SF contains a total of 29 items comprising six subscales. The results of both confirmatory and exploratory factor analyses provided support for the scaling algorithm. The DFS-SF subscales showed good internal consistency, reliability and construct validity, and demonstrated sensitivity to ulcer healing. CONCLUSIONS: The results of this investigation indicate that the DFS-SF has good psychometric properties and replicability.
|
Authors | Carla M Bann, Sheri E Fehnel, Dennis D Gagnon |
Journal | PharmacoEconomics
(Pharmacoeconomics)
Vol. 21
Issue 17
Pg. 1277-90
( 2003)
ISSN: 1170-7690 [Print] New Zealand |
PMID | 14986739
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Diabetic Foot
(psychology)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Psychometrics
(methods)
- Quality of Life
(psychology)
- Reproducibility of Results
- Severity of Illness Index
- Sickness Impact Profile
|